ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to continue dosing for the potential treatment of their condition.

NCT Number	NCT06462547
Lead Sponsor	Inozyme Pharma
Conditions	Gene Mutations, Pseudoxanthoma Elasticum, Arterial Calcification, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets Type 2
Enrollment	200 participants
Start Date	2024-06-19
Primary Completion	2030-11 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2024-11-29